Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 25, 2002
-
ARCHIVE Importance of Training Rheumatologists Stressed: RDIC Seminar
March 18, 2002
-
ARCHIVE Nippon Roche to Participate in Multinational Study on Herceptin: JSMO Meeting
March 18, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 18, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
March 18, 2002
-
ARCHIVE New NHI Prices to Be Effective on April 1
March 18, 2002
-
ARCHIVE Committee to Propose Intellectual Property Strategy by Summer
March 18, 2002
-
ARCHIVE Korosho's PAL Amendment Bill Approved by LDP
March 18, 2002
-
ARCHIVE Pravastatin Is Beneficial for Postmenopausal Hyperlipidemia: Seminar
March 18, 2002
-
ARCHIVE Sales of Bonalon Remain at 60% of Target
March 18, 2002
-
ARCHIVE Evidence-Based Infection Control GL Established
March 18, 2002
-
ARCHIVE Eisai Aims at Sales of \550 Bil. in FY2006: President Naito
March 18, 2002
-
ARCHIVE ICH Meeting in Brussels Reported by Korosho
March 18, 2002
-
ARCHIVE Giving Employees the Dream of Creating Major Firm: Mr Mascarenhas of Eli Lilly Japan
March 18, 2002
-
ARCHIVE Reform Must Be Carried Out at Any Cost: Health Minister
March 18, 2002
-
COLUMN Maurer's Healthcare Insight (26)
March 18, 2002
-
ARCHIVE Healthcare Reform Bills Approved by Government
March 18, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
March 18, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 18, 2002
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
March 18, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…